Kim Davis
Known title: Chief Legal OfficerCIK: 0001965590
Associated companies
Transaction History
| ZURA | ▲ Buy | Grant | 1,000 | $0 | 9/16/2024 | View on chart |
| ZURA | ▲ Buy | Grant | 500 | $0 | 10/1/2023 | View on chart |
| ZURA | ▲ Buy | Grant | 492,381 | $0 | 5/18/2023 | View on chart |
| ZURA | ▲ Buy | Grant | 1,000 | $0 | 9/16/2024 | View on chart |
| ZURA | ▲ Buy | Grant | 500 | $0 | 10/1/2023 | View on chart |
| ZURA | ▲ Buy | Grant | 492,381 | $0 | 5/18/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Zura Bio Named Top Pick by Guggenheim Amid Recent Price Gains
Zura Bio was highlighted as a top pick by Guggenheim, contributing to its recent upward movement alongside other stocks. The company's share price has risen, though it remains well below the average analyst target of $18.00. Current trading levels sit near the lower end of its 52-week range, reflecting a significant gap between current market price and long-term valuation estimates.
Zura Bio Named Top Pick by Guggenheim Amid Recent Price Gains. Zura Bio was highlighted as a top pick by Guggenheim, contributing to its recent upward movement alongside other stocks. The company's share price has risen, though it remains well below the average analyst target of $18.00. Current trading levels sit near the lower end of its 52-week range, reflecting a significant gap between current market price and long-term valuation estimates.